China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection by the Ministry of Health of Egypt for its Tongboli, a biosimilar version of Novo Nordisk’s GLP-1 receptor agonist Victoza (liraglutide), is well underway in the country.
Product Background
Tongboli, the Victoza knockoff, received marketing approval in China in November 2023. The product is being commercialized by Kexing Biopharm Co., Ltd. (SHA: 688136) in overseas emerging markets, including Egypt, following a licensing agreement signed in December 2022.
GMP Inspection
The GMP inspection in Egypt is a crucial step for Tonghua Dongbao to ensure that its manufacturing processes meet international standards. This will facilitate the company’s efforts to expand its market presence in the region and globally.-Fineline Info & Tech
